Ionis Pharmaceuticals Inc
(FRA:ISI)
€
33.48
-0.13 (-0.39%)
Market Cap: 5.40 Bil
Enterprise Value: 4.42 Bil
PE Ratio: 0
PB Ratio: 8.55
GF Score: 60/100 Ionis Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 02:55PM GMT
Release Date Price:
€30.03
(-1.38%)
Luca Issi
RBC Capital Markets, Research Division - Research Analyst
Well, great. Hello, everybody, and thank you for dialing in. My name is Luca Issi. I'm a senior biotech analyst here at RBC Capital Markets. And today is our great privilege to have Beth Hougen, the CFO of Ionis for a fireside chat. Thanks so much for joining us. How are you doing today?
Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Great. Thanks for having this, Luca. I appreciate it.
Questions & Answers
Luca Issi
RBC Capital Markets, Research Division - Research Analyst
That's fantastic. So can you maybe start with a question on Akcea. You obviously recently completed the acquisition of Akcea. Can you remind us the rationale behind that decision? And maybe just give us a quick update on the process? And how should we think about cost synergies going forward here?
Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO
Sure.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot